Holen Sie sich die Stockscreener-App
70.22
2.17%
1.49
Vorhandelsmarkt:
69.93
-0.29
-0.41%
Schlusskurs vom Vortag:
$68.73
Offen:
$69
24-Stunden-Volumen:
425.44K
Relative Volume:
0.78
Marktkapitalisierung:
$2.02B
Einnahmen:
$234.60M
Nettoeinkommen (Verlust:
$-13.23M
KGV:
-134.88
EPS:
-0.5206
Netto-Cashflow:
$19.61M
1W Leistung:
+13.02%
1M Leistung:
+8.35%
6M Leistung:
+120.47%
1J Leistung:
+293.17%
1-Tages-Spanne:
$66.14
$71.29
1-Wochen-Bereich:
$62.72
$73.30
52-Wochen-Spanne:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
70.22 | 2.02B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
JPMorgan Chase Reduces Stake in AnaptysBio Biotech Firm - National Today
AnaptysBio, Inc. $ANAB Shares Sold by JPMorgan Chase & Co. - MarketBeat
Aug Macro: Can AnaptysBio Inc reach all time highs this year2026 Trading Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - MSN
ANAPTYSBIO INC- W/I (ANABV) Stock Chart - ChartMill
ANABV Technical Analysis | Trend, Signals & Chart Patterns | ANAPTYSBIO INC- W/I (NASDAQ:ANABV) - ChartMill
AnaptysBio stock hits 52-week high at 68.46 USD By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighTime to Buy? - MarketBeat
AnaptysBio stock hits 52-week high at 68.46 USD - Investing.com
Equity in earnings of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Pretax income of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Total equity of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Total assets of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Net debt of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
AnaptysBio, Inc. Balance Sheet – NASDAQ:ANABV - TradingView — Track All Markets
After tax other income/expense of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Behavioral Patterns of ANAB and Institutional Flows - Stock Traders Daily
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Return on assets % of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Asset turnover of AnaptysBio, Inc. – NASDAQ:ANABV - tradingview.com
Quick ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Book value per share of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView
Current ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Enterprise value to EBITDA ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Debt to assets ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Price to cash flow ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Price to book ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
EBITDA margin % of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
AnaptysBio: Upside Constrained By Undifferentiated Data, Legal Uncertainties - Seeking Alpha
Debt to equity ratio of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Enterprise value of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
AnaptysBio, Inc. Statistics – NASDAQ:ANABV - TradingView — Track All Markets
AnaptysBio, Inc. Earnings and Revenue – NASDAQ:ANABV - TradingView — Track All Markets
ANABV Price Today: AnaptysBio, Inc. Stock Price, Quote & Chart - MEXC
ANABV interactive stock chart | ANAPTYSBIO INC stock - Yahoo Finance Singapore
AnaptysBio, Inc. Income Statement – NASDAQ:ANABV - TradingView — Track All Markets
Free float of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
Basic earnings per share (basic EPS) of AnaptysBio, Inc. – NASDAQ:ANABV - TradingView — Track All Markets
AnaptysBio, Inc. Dividends – NASDAQ:ANABV - TradingView — Track All Markets
Trade Alert: Independent Director Of AnaptysBio John Schmid Has Sold Stock - simplywall.st
AnaptysBio, Inc.: Target Price Consensus and Analysts Recommendations | ANABV | US0327242055 - marketscreener.com
Price performance - Yahoo Finance Singapore
Risk On: Will AnaptysBio Inc face regulatory challengesPortfolio Return Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Trading Up 7.6%Still a Buy? - MarketBeat
AnaptysBio, Inc. (ANAB) stock price, news, quote and history - Yahoo Finance UK
Spin-off Imminent At AnaptysBio - San Diego Business Journal
AnaptysBio, Inc. Common Stock When Issued (ANABV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings - Yahoo Finance
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $69 - Moomoo
Director Susannah Gray at AnaptysBio (ANAB) submits initial Form 3 - Stock Titan
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):